This is a powerful patent that covers essentially the endothelial precursor cell. The importance of endothelial precursors is their ability to induce angiogenesis.
The patent has claims on any CD34 + VEGF R+ cell, as well as CD133+, VEGF R+ endothelial stem cell.
Sources of these cells covered in the claims include circulating blood, cord blood, mobilized blood, and bone marrow.
The question is, the trials that are currently using autologous bone marrow cells for induction of angiogenesis...if the active cell is found to be CD34+ VEGF-R+, which it most likely is...then this patent will be very valuable to anyone operating in this area.
View this patent on the USPTO website.
You must be signed-in to add your comments.
Sign-in now or Join the StemCellPatents.com Community for free.